VLA1701

VLA1701 is an investigational, oral, inactivated combination vaccine developed by Valneva for the prevention of cholera and diarrhea caused by enterotoxigenic *Escherichia coli* (ETEC). The vaccine is designed to provide dual protection against *Vibrio cholerae* and ETEC, which are major causes of travelers' diarrhea and endemic diarrheal disease in low-resource settings. VLA1701 builds upon the technology of the licensed cholera vaccine Dukoral, typically consisting of killed *Vibrio cholerae* O1 bacteria and a recombinant cholera toxin B subunit (rCTB). Because the heat-labile toxin (LT) produced by ETEC is immunologically and structurally similar to the cholera toxin B subunit, the vaccine induces cross-protective mucosal immunity against both pathogens. It is currently being evaluated in Phase II clinical trials, including human challenge models, to confirm its safety and efficacy.

Other names

Valneva oral cholera and ETEC vaccineOral cholera and ETEC vaccine